| 师 瑞,雷培森,阿 明.CIK 细胞介导的获得性免疫在血液系统恶性肿瘤中的研究进展[J].肿瘤学杂志,2016,22(6):492-500. |
| CIK 细胞介导的获得性免疫在血液系统恶性肿瘤中的研究进展 |
| Research Progress of Cytokine-induced Killer (CIK) Cells Based Adoptive Immunotherapy in Hematological Malignancies |
| 投稿时间：2015-10-28 |
| DOI：10.11735/j.issn.1671-170X.2016.06.B012 |
|
 |
| 中文关键词: CIK细胞 临床试验 免疫治疗 血液系统恶性肿瘤 |
| 英文关键词:CIK cell clinical trial immunotherapy hematological malignancies |
| 基金项目: |
|
| 摘要点击次数: 2504 |
| 全文下载次数: 935 |
| 中文摘要: |
| 摘 要：细胞因子诱导的杀伤细胞（CIK）细胞是通过采集患者外周血的单核细胞，在体外经多种细胞因子诱导和培养后获得的一类具有非主要组织相容性抗原限制性（MHC）杀瘤活性的免疫细胞，同时表达CD3 和CD56这两种膜蛋白分子，具有T 淋巴细胞的强大抗瘤活性和NK细胞的非MHC限制性杀瘤的优点。因其易获得，体外高扩增率以及非MHC限制性等优点，使之成为肿瘤获得性生物免疫治疗中的热点。在体外及动物试验中，CIK细胞对实体瘤和血液系统恶性肿瘤同样具有有效的细胞毒性作用，临床研究显示，CIK细胞免疫治疗对于肿瘤患者，甚至是晚期肿瘤患者疗效肯定，与传统治疗方法具有协同抗瘤作用。本文将讨论CIK免疫治疗在血液系统恶性肿瘤中的研究进展及未来发展趋势，并将最新的重点研究成果作一回顾。总体来讲，研究显示，CIK细胞在控制血液系统肿瘤生长、延长生存时间以及改善生活质量上具有肯定疗效。然而，目前为止，仍缺乏明确的能够用于临床治疗的应用规范。 |
| 英文摘要: |
| Abstract：Cytokine induced killer (CIK) cells are immune effector cells which could be expanded from peripheral blood mononuclear cells (PBMC) cultured with many cytokines. A consistent subset of mature CIK cells presents a CD3(+)CD56(+) phenotype. Feature both T cell cytotoxic activity and natural killer(NK)-like major histocompatibility complex (MHC)-unrestricted antitumor activity. The easy availability，high proliferation rate and non-MHC restricted cytolytic profile，making them an attractive approach for adoptive immunotherapy. CIK cells have shown considerable cytotoxicity against both solid tumors and hematological malignancies in vitro and in animal studies. Amount of phase Ⅰ/Ⅱ clinical studies demonstrated the feasibility and efficacy of CIK cell immunotherapy in cancer patients，even at advanced disease stages. Meanwhile，the combination application of CIK with standard therapeutic procedures revealed synergistic antitumor effects. In this article，We give insight into the latest advances in the CIK cell immunotherapy of hematological malignancies and look into future perspectives of adoptive immunotherapy. In general，CIK cells demonstrate a considerable effect on the patients with hematological malignancies，as evidenced by complete remissions，prolong survival durations and improve quality of life. However，the optimal application procedure for clinical practice has still to be developed. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |